Phase II study on lapatinib in advanced EGFR-positive chordoma †

Overview of attention for article published in Annals of Oncology, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
f1000: 1 research highlight platform

Readers on

mendeley: 80 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,936 followers.

Phase II trial shows that 22% of patients with advanced EGFR positive chordoma benefitted from Lapatinib... http://t.co/NWPOTBXgv1

Phase II trial shows that 22% of patients with advanced EGFR positive chordoma benefitted from Lapatinib... http://t.co/NWPOTBXgv1

Phase II trial shows that 22% of patients with advanced EGFR positive chordoma benefitted from Lapatinib... http://t.co/NWPOTBXgv1

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.